7 months ago
Sigachi Industries Advances Cystic Fibrosis APIs
Sigachi Industries, a big Indian medicine company, has made a new mix of medicines for Cystic Fibrosis, a serious lung disease.
This new mix includes three special ingredients: Vanzacaftor, Tezacaftor, and Deutivacaftor.
The company thinks this new medicine can make them about ₹250 crore every year starting in 2026.
They are also looking for partners to help them sell these medicines.
The company has been making medicines for 36 years and has factories in different places in India.
They are excited about this new medicine because it is special and hard for other companies to copy.
This means they can make good money from it for a long time.
Sigachi Industries has developed a new combination of APIs for Cystic Fibrosis: Vanzacaftor, Tezacaftor, and Deutivacaftor.
The company estimates a revenue potential of ₹250 crore per annum starting from Q4 FY2026-27.
Sigachi is exploring strategic collaborations for R&D and commercial supply of these CF APIs.
The global cystic fibrosis therapeutics market is valued at over USD 10 billion.
The innovator patent for Vanzacaftor extends until 2039, providing long-term commercial opportunities.
- Who
- Sigachi Industries Ltd.
- What
- Development of Cystic Fibrosis APIs
- Where
- Hyderabad, Telangana, India
- When
- Commencing from Q4 FY2026-27
- Why
- To expand presence in complex, high-value specialty APIs
Key facts
- Company
- Sigachi Industries Ltd.
- APIs Developed
- Vanzacaftor, Tezacaftor, Deutivacaftor
- Market Potential
- ₹250 crore per annum
- Expected Revenue Start
- Q4 FY2026-27
- Patent Protection
- Until 2039
- Global Market Size
- USD 10 billion
- Company Facilities
- 5 locations in Telangana, Gujarat, Karnataka
- Company Experience
- 36 years
Quotes
Lijo Chacko
Deputy Group CEO, Sigachi Industries Limited
“This milestone reflects Sigachi’s focused strategy of building depth in complex and differentiated APIs with long-term growth visibility. Our continued investments in R&D and partnerships are aimed at strengthening our position in high-entry-barrier specialty segments and creating sustainable value for stakeholders.”
theprint.in
